Compass Pathways (NASDAQ:CMPS) Trading Down 5.5% – What’s Next?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) traded down 5.5% during trading on Monday . The company traded as low as $11.75 and last traded at $11.6750. 2,908,358 shares changed hands during trading, a decline of 24% from the average daily volume of 3,804,719 shares. The stock had previously closed at $12.35.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CMPS. Stifel Nicolaus upped their target price on shares of Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Jefferies Financial Group restated a “buy” rating on shares of Compass Pathways in a research report on Tuesday, July 7th. Raymond James Financial reissued a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Wall Street Zen raised Compass Pathways from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, BTIG Research upped their price objective on Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.15.

Compass Pathways Stock Down 4.0%

The company has a current ratio of 3.32, a quick ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm’s 50 day moving average price is $12.35 and its two-hundred day moving average price is $8.85. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of -3.77 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Sell-side analysts anticipate that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

A number of institutional investors have recently bought and sold shares of CMPS. EverSource Wealth Advisors LLC raised its position in shares of Compass Pathways by 67.7% in the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd acquired a new position in Compass Pathways in the fourth quarter valued at about $38,000. Parallel Advisors LLC raised its stake in Compass Pathways by 8,450.6% in the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after purchasing an additional 7,183 shares in the last quarter. Advisory Services Network LLC bought a new stake in Compass Pathways during the third quarter worth about $41,000. Finally, North Star Investment Management Corp. lifted its position in Compass Pathways by 1,354.0% during the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after purchasing an additional 7,000 shares during the period. Institutional investors own 46.19% of the company’s stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.